Investors & Media

Webcast ImageWebcast
Q4 2016 Ionis Pharmaceuticals Inc Earnings Conference Call (Live)
02/28/17 at 11:30 a.m. ET
Q4 2016 Ionis Pharmaceuticals Inc Earnings Conference Call
Tuesday, February 28, 2017 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Cowen and Company 37th Annual Health Care Conference (Live)
03/08/17 at 8:00 a.m. ET
Cowen and Company 37th Annual Health Care Conference
Wednesday, March 8, 2017 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
DateTitle
02/16/17Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
- Ionis and Akcea to receive $75 million up-front payment - Deal valued at more than $1 billion CARLSBAD, Calif. and CAMBRIDGE, Mass., Feb. 16, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced today they have closed on their exclusive, worldwide option and collaboration agreement with Novartis to develop and commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx following clearance unde... 
02/15/17Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call
Webcast scheduled for Tuesday, February 28 at 11:30 a.m. Eastern Time CARLSBAD, Calif., Feb. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, February 28 at 11:30 a.m. Eastern Time to discuss its 2016 financial results and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com.  A ... 
02/14/17Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
CARLSBAD, Calif., Feb. 14, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the advancement of IONIS-FXIRx  in clinical development under an existing exclusive license agreement with Bayer. Under this agreement, Ionis will also initiate development of IONIS-FXI-LRx, which uses Ionis' proprietary LIgand Conjugated Antisense, or LICA, technology.  In conjunction with the decision to advance these programs, Ionis will receive a $75 million payment from Bayer.   ... 
02/02/17Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
CARLSBAD, Calif., Feb. 2, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development.  ... 
Upcoming EventsMore >>
DateTitle
02/28/17 11:30 a.m. ET
Q4 2016 Ionis Pharmaceuticals Inc Earnings Conference Call
Supporting Materials
03/08/17 8:00 a.m. ET
Cowen and Company 37th Annual Health Care Conference
Supporting Materials

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.